Compare HLN & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | KVUE |
|---|---|---|
| Founded | 2022 | 2022 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Specialty Chemicals |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8B | 34.2B |
| IPO Year | 2021 | 2023 |
| Metric | HLN | KVUE |
|---|---|---|
| Price | $9.17 | $17.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $19.45 |
| AVG Volume (30 Days) | 18.7M | ★ 24.6M |
| Earning Date | 02-26-2026 | 05-07-2026 |
| Dividend Yield | 1.94% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $6.55 | $4.85 |
| Revenue Next Year | $4.42 | $2.63 |
| P/E Ratio | $49.05 | ★ $37.11 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.65 | $14.02 |
| 52 Week High | $11.28 | $20.13 |
| Indicator | HLN | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 40.62 |
| Support Level | $9.08 | $17.39 |
| Resistance Level | $9.20 | $17.88 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.24 | 45.95 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.